Medtronic Retires 55M Shares via Diabetes Spinoff, Eyes Dividend King Status

What happened

Medtronic completed the spinoff of its diabetes segment through a split-off exchange that retired 55 million shares without using cash. The transaction reduces the company's outstanding share count by approximately 4%, providing an immediate EPS tailwind. The diabetes business, which generated $2.755 billion in fiscal 2025 revenue, was the smallest and slowest-growing of Medtronic's four segments. This move aligns with management's focus on higher-growth cardiovascular and medical-surgical markets and follows activist investor pressure from Elliott. The company is now positioned to achieve Dividend King status with over 50 consecutive years of dividend increases, though core risks around litigation and PFA competition remain.

Implication

Over the long term, the spinoff allows Medtronic to concentrate resources on higher-growth businesses and simplifies its story, potentially improving the multiple if execution follows. However, the investment case still hinges on durable PFA share gains, successful Hugo commercialization, and resolution of contingent liabilities. We maintain a WAIT rating until clearer evidence of these catalysts emerges.

Thesis delta

The diabetes spinoff and share retirement is a minor positive delta for Medtronic's thesis: it reduces share count without cash, improves EPS, and demonstrates portfolio focus. However, this does not alter the fundamental risks tied to competitive dynamics in PFA and the Applied litigation outcome. We keep our WAIT rating and attractive entry around $90.